Erika Martinelli

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO.

Y. Yen, G. Bhattacharyya, S. Choo, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer

E. Van Cutsem, J. Tabernero, F. Ciardiello, 2015, British Journal of Cancer.

Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study.

F. J. Ramos, J. Baselga, J. Tabernero, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy.

G. Tortora, F. Ciardiello, R. Bianco, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.

G. Botti, N. Normanno, F. Fenizia, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial.

G. Botti, N. Normanno, F. Fenizia, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures

S. Zappavigna, M. Caraglia, A. Fiorelli, 2019, Journal of Experimental & Clinical Cancer Research.

Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab.

L. Antonuzzo, L. Rimassa, T. Pressiani, 2024, Targeted oncology.